Global leader in chlorine dioxide disinfectant solutions for infection prevention and contamination control

Tristel plc

Tristel plc has a consistent record of revenue growth as an AIM listed public company. It is one of only a few businesses worldwide that specialises in infection prevention in human and animal healthcare and contamination control in industry.

Since its IPO in June 2005, Tristel has established itself as a world class manufacturer of liquid chemical hygiene products.

This Investor Centre was last updated on 17/08/2017.  The information contained within it is disclosed in accordance with AIM Rule 26. The Company is Subject to the UK City Code on Takeovers and Mergers.

The Tristel story began in 1993 when the founding shareholders developed a proprietary chlorine dioxide formulation to be used for the disinfection of flexible endoscopes to replace glutaraldehyde. Glutaraldehyde was at the time used universally throughout all hospitals in the United Kingdom, and indeed worldwide, for the disinfection of heat sensitive medical instruments. However, it was known to be toxic.

During the course of the following decade Tristel gradually captured significant market share in the United Kingdom hospital market.  In June 2005 Tristel plc was listed on the London Stock Exchange AIM market.

By this time the Company had developed a broader vision for the use of its chlorine dioxide chemistry and had set in train its strategy to apply the chemistry to the four vectors of transmission of infection in a hospital: Instruments, Surfaces, Water and Skin.

A key milestone in the development of the Tristel group was the establishment of its manufacturing plant in Cambridgeshire in 2007.

Having established its capability as an ISO 9001:2008 and BS EN 13485:2003 manufacturer of high-level disinfectants, in 2009 Tristel acquired the intellectual property and manufacturing rights for the portfolio of disinfectants sold by Medichem International (Marketing) and used in animal healthcare worldwide.  Tristel manufactured these products for Medichem until March 2012 when it created its Anistel brand and has since served the animal healthcare market directly.

Following its initial public offering Tristel also embarked upon its plan to take its products into overseas markets, establishing distributors throughout Continental Europe, the Middle and the Far East.  It is one of the stated aims of the Group to be a recognised force in the global infection control industry.  In the pursuit of this aim, Tristel has established subsidiaries and associated companies in Australia, New Zealand, Hong Kong, China, Italy, Germany, Russia and the USA

Tristel also manufactures and sells contamination control products under the Crystel brand to the pharmaceutical and personal care industry.  For this market, the Company has established a Class 6 cleanroom to enable it to manufacture sterile-packed disinfectant products.

Advisors

Financial Performance

Board & Governance

Board of Directors

  • Francisco Soler
  • Paul Swinney
  • Liz Dixon
  • Paul Barnes
  • David Orr    

 

Investor News

Investor Information

Listing Information

Business Summary: Manufacture and sale of products and systems addressing infection and contamination control in human and animal healthcare, pharmaceutical and personal care manufacturing plants and industrial water systems.

Sector: Healthcare equipment & services.

Index: Tristel plc shares are listed on the AIM (Alternative Investment Market). There are no other exchanges or trading platforms on which Tristel plc has applied or agreed to have any of its securities admitted or traded. There are no restrictions on the transfer of Tristel plc’s AIM securities.

Ticker Symbol: TSTL

Shares in Issue at 27 July 2017: 42,803,917 (Ord 1p)

 

Investor Relations Contacts

Welcome to Tristel
Please select from the following